Clinical outcomes and their relationship with tigecycline exposure in critically ill patients with drug resistant infections
Wei Su, Shuping Song, Qing Tang, Binbin Feng, Yinshan Wu, Haitao Yu, Feng Guo, Zhenwei Yu · 2026
Read Clinical outcomes and their relationship with tigecycline exposure in critically ill patients with drug resistant infections by Wei Su, Shuping Song, Qing Tang, Binbin Feng, Yinshan Wu, Haitao Yu, Feng Guo, Zhenwei Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623591.txt.
Description
Wei Su and seven co-authors examine how much of a last-resort antibiotic critically ill patients actually get, and whether more helps, in this 2026 study. Tigecycline is a fallback drug against carbapenem-resistant bacteria. Levels vary wildly between patients, and the exposure target behind dosing was weakly supported.
The prospective study followed 130 intensive care patients, mostly with lung infections, and the commonest pathogen was a resistant Acinetobacter. Half responded to treatment, while 36.2 percent died within twenty-eight days. Blood and clotting measures predicted who responded, but drug exposure itself pointed the wrong way: higher exposure tracked with worse response. The commonest side effect was a drop in the clotting protein fibrinogen. The authors say the outcome was acceptable overall, yet the exposure paradox means the dosing theory for this drug needs a fresh look.
Catalog record
| CREATOR | Wei Su, Shuping Song, Qing Tang, Binbin Feng, Yinshan Wu, Haitao Yu, Feng Guo, Zhenwei Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |